Literature DB >> 26762570

Addressing potential prior-data conflict when using informative priors in proof-of-concept studies.

Timothy Mutsvari1, Dominique Tytgat2, Rosalind Walley3.   

Abstract

Bayesian methods are increasingly used in proof-of-concept studies. An important benefit of these methods is the potential to use informative priors, thereby reducing sample size. This is particularly relevant for treatment arms where there is a substantial amount of historical information such as placebo and active comparators. One issue with using an informative prior is the possibility of a mismatch between the informative prior and the observed data, referred to as prior-data conflict. We focus on two methods for dealing with this: a testing approach and a mixture prior approach. The testing approach assesses prior-data conflict by comparing the observed data to the prior predictive distribution and resorting to a non-informative prior if prior-data conflict is declared. The mixture prior approach uses a prior with a precise and diffuse component. We assess these approaches for the normal case via simulation and show they have some attractive features as compared with the standard one-component informative prior. For example, when the discrepancy between the prior and the data is sufficiently marked, and intuitively, one feels less certain about the results, both the testing and mixture approaches typically yield wider posterior-credible intervals than when there is no discrepancy. In contrast, when there is no discrepancy, the results of these approaches are typically similar to the standard approach. Whilst for any specific study, the operating characteristics of any selected approach should be assessed and agreed at the design stage; we believe these two approaches are each worthy of consideration.
Copyright © 2015 John Wiley & Sons, Ltd.

Keywords:  Bayesian analysis; informative prior; mixture prior; prior-data conflict; proof-of-concept; robust prior

Mesh:

Year:  2015        PMID: 26762570     DOI: 10.1002/pst.1722

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  3 in total

1.  Borrowing of information across patient subgroups in a basket trial based on distributional discrepancy.

Authors:  Haiyan Zheng; James M S Wason
Journal:  Biostatistics       Date:  2022-01-13       Impact factor: 5.899

2.  Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study.

Authors:  Caroline Brard; Lisa V Hampson; Nathalie Gaspar; Marie-Cécile Le Deley; Gwénaël Le Teuff
Journal:  BMC Med Res Methodol       Date:  2019-04-24       Impact factor: 4.615

3.  Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma.

Authors:  Caroline Brard; Sophie Piperno-Neumann; Jessy Delaye; Laurence Brugières; Lisa V Hampson; Gwénaël Le Teuff; Marie-Cécile Le Deley; Nathalie Gaspar
Journal:  BMJ Open       Date:  2019-05-19       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.